<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dyadic International Inc — News on 6ix</title>
<link>https://6ix.com/company/dyadic-international-inc</link>
<description>Latest news and press releases for Dyadic International Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dyadic-international-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835607c78dffbe2df0ee079.webp</url>
<title>Dyadic International Inc</title>
<link>https://6ix.com/company/dyadic-international-inc</link>
</image>
<item>
<title>Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-to-report-q1-2026-financial-results-and-host-conference-call-on-wednesday-may-13-2026</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-to-report-q1-2026-financial-results-and-host-conference-call-on-wednesday-may-13-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial result</description>
</item>
<item>
<title>Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-announces-2025-financial-results-and-highlights-recent-company-progress</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-announces-2025-financial-results-and-highlights-recent-company-progress</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to</description>
</item>
<item>
<title>Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-announces-commercial-distribution-partnership-with-ibt-bioservices</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-announces-commercial-distribution-partnership-with-ibt-bioservices</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing</title>
<link>https://6ix.com/company/dyadic-international-inc/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-6</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/life-sciences-virtual-investor-forum-presentations-now-available-for-online-viewing-6</guid>
<pubDate>Fri, 13 Mar 2026 12:35:00 GMT</pubDate>
<description>NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging tec</description>
</item>
<item>
<title>Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-to-report-2025-full-year-financial-results-and-host-conference-call-on-wednesday-march-25-2026-7</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-to-report-2025-full-year-financial-results-and-host-conference-call-on-wednesday-march-25-2026-7</guid>
<pubDate>Wed, 11 Mar 2026 20:10:00 GMT</pubDate>
<description>JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial result</description>
</item>
<item>
<title>Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th</title>
<link>https://6ix.com/company/dyadic-international-inc/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th-1</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/life-sciences-virtual-investor-forum-agenda-announced-for-march-11th-and-12th-1</guid>
<pubDate>Tue, 10 Mar 2026 14:21:00 GMT</pubDate>
<description>Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.comNEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the on</description>
</item>
<item>
<title>Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-and-fermbox-bio-launch-first-product-under-expanded-collaboration-animal-origin-free-recombinant-dnase-i-rnase-free</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-and-fermbox-bio-launch-first-product-under-expanded-collaboration-animal-origin-free-recombinant-dnase-i-rnase-free</guid>
<pubDate>Wed, 04 Mar 2026 12:20:00 GMT</pubDate>
<description>JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Fermbox Bio (“Fermbox”), a biotech research and manufacturing company developing sustainable bio-based products through precision fermentation and advanced biotechnology tool</description>
</item>
<item>
<title>Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-and-inzymes-aps-announce-planned-2026-commercialization-of-non-animal-dairy-enzyme-following-achievement-of-development-milestone</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-and-inzymes-aps-announce-planned-2026-commercialization-of-non-animal-dairy-enzyme-following-achievement-of-development-milestone</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:</description>
</item>
<item>
<title>Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-proliant-health-122500745</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-proliant-health-122500745</guid>
<pubDate>Tue, 17 Feb 2026 12:25:00 GMT</pubDate>
<description>JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bio-industrial uses, and Proliant Health & Biologicals (“Proliant”), a leading global producer of albumin and other purified proteins for life science, nutrition, and diagnostic applications, today announ</description>
</item>
<item>
<title>Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-fermbox-bio-expand-strategic-122000416</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-fermbox-bio-expand-strategic-122000416</guid>
<pubDate>Wed, 17 Dec 2025 12:20:00 GMT</pubDate>
<description>JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering sustainable</description>
</item>
<item>
<title>Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-establishes-commercial-122000302</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-establishes-commercial-122000302</guid>
<pubDate>Mon, 15 Dec 2025 12:20:00 GMT</pubDate>
<description>JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets today announced that it has entered into a commercial agreement with Opes Diagnostics Limited (“Opes”) to support the commercial launch of Dyadic’s recombinant human transferrin, bovine transferrin, human FGF, and bovine FGF products f</description>
</item>
<item>
<title>Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-brig-bio-sign-development-122500908</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-brig-bio-sign-development-122500908</guid>
<pubDate>Mon, 01 Dec 2025 12:25:00 GMT</pubDate>
<description>JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets, and BRIG BIO (official legal entity The Protein Collective B.V.), a Netherlands-based developer of next-generation recombinant dairy ingredients, today announced the signing of a Development and Commercialization Agreemen</description>
</item>
<item>
<title>Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-announces-third-quarter-2025-210500032</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-announces-third-quarter-2025-210500032</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced multiple recombinant protein programs toward commercializationAchieved key development and commercial milestones across life sciences and nutrition marketsFirst purchase order received in cell culture media and molecular biology reagent segmentsSecured ERS Genomics CRISPR license to optimize productio</description>
</item>
<item>
<title>ERS Genomics and Dyadic Applied BioSolutions Sign CRISPR/Cas9 License Agreement</title>
<link>https://6ix.com/company/dyadic-international-inc/news/ers-genomics-and-dyadic-applied-biosolutions-sign-crisprcas9-license-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/ers-genomics-and-dyadic-applied-biosolutions-sign-crisprcas9-license-agreement</guid>
<pubDate>Mon, 10 Nov 2025 15:50:00 GMT</pubDate>
<description>ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced they have signed a non-exclusive agreement granting access to ERS' foundational CRISPR/Cas9 patent portfolio.</description>
</item>
<item>
<title>Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-expands-genetic-122500634</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-expands-genetic-122500634</guid>
<pubDate>Mon, 10 Nov 2025 12:25:00 GMT</pubDate>
<description>JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enh</description>
</item>
<item>
<title>Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-report-third-quarter-2025-112500551</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-report-third-quarter-2025-112500551</guid>
<pubDate>Wed, 29 Oct 2025 11:25:00 GMT</pubDate>
<description>JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results</description>
</item>
<item>
<title>Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-announces-milestone-123000425</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-applied-biosolutions-announces-milestone-123000425</guid>
<pubDate>Mon, 06 Oct 2025 12:30:00 GMT</pubDate>
<description>JUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced the achievement of additional milestone payments in its collaborations with Proliant Health & Biologicals in life sciences and Inzymes ApS in food and nutrition, along with upd</description>
</item>
<item>
<title>Dyadic to Present at Investor Conferences and BPI East</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-present-investor-conferences-bpi-130000746</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-present-investor-conferences-bpi-130000746</guid>
<pubDate>Thu, 04 Sep 2025 13:00:00 GMT</pubDate>
<description>JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that Joe Hazelton, Dyadic’s</description>
</item>
<item>
<title>Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-reports-second-quarter-2025-200100281</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-reports-second-quarter-2025-200100281</guid>
<pubDate>Wed, 13 Aug 2025 20:01:00 GMT</pubDate>
<description>Completed Strategic Leadership and Operational Transformation from R&D to Commercial OperationsRebranded as Dyadic Applied BioSolutions to Reflect Our New Operational PrioritiesFull Redesign of Corporate Website to Prioritize Commercial Execution and Long-term Value CreationCompleted $5.3 million Equity Offering to Strengthen Liquidity and Help Fund Pipeline and Commercial GrowthAchieved Key Development and Commercial Milestones in Life Sciences and Nutrition MarketsAdvanced Multiple Recombinant</description>
</item>
<item>
<title>Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025</title>
<link>https://6ix.com/company/dyadic-international-inc/news/dyadic-report-second-quarter-2025-201100357</link>
<guid isPermaLink="true">https://6ix.com/company/dyadic-international-inc/news/dyadic-report-second-quarter-2025-201100357</guid>
<pubDate>Tue, 05 Aug 2025 20:11:00 GMT</pubDate>
<description>JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and h</description>
</item>
</channel>
</rss>